DarioHealth Corp. Common Stock
DRIODarioHealth Corp. (DRIO) is a digital health company that develops and offers integrated solutions for chronic disease management, particularly focusing on diabetes care. Its platform combines hardware, software, and personalized coaching to help users monitor and improve their health outcomes. The company's approach emphasizes data-driven and user-centric tools to facilitate better disease management and support healthier lifestyles.
Company News
DarioHealth (NASDAQ: DRIO) reported Q1 2026 results with second consecutive quarter of sequential revenue growth to $5.6 million, though down year-over-year due to non-recurrence of pharmaceutical customer revenue. The company achieved 21% year-over-year operating expense reduction and improved operating loss by 22% YoY. Channel partnerships now ...
DarioHealth Corp. (NASDAQ: DRIO), a digital health company specializing in chronic condition management, announced it will release its Q1 2026 financial results on May 13, 2026 at 8:30 a.m. ET. The company will host a conference call and webcast with CEO Erez Raphael, President Steven Nelson, and CFO Chen Franco-Yehuda to discuss results.
A study published in JMIR by Sanofi and Symphony Health revealed that DarioHealth's digital diabetes intervention platform can reduce healthcare costs by an estimated $5,077 per user annually, with 23% lower hospitalization rates and 26% lower all-cause medical charges.
DarioHealth reported Q3 2025 revenue of $5.0 million, down from $7.4 million in Q3 2024, but highlighted strong business fundamentals including 60% GAAP gross margin and 45 new signed accounts for 2026 revenue.
DarioHealth revealed research at ISPOR Europe 2025 showing its digital health platform can significantly reduce medical costs, particularly among high-risk populations, by using connected devices, AI-driven insights, and human coaching across multiple chronic conditions.
